Drug Profile
Research programme: cancer therapeutics - CorMedix/NanoProteagen
Alternative Names: CRMD 005/vincristine; CRMD-005; Taurolidine/vincristine - CorMedix; Vincristine/taurolidine - CorMedixLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator CorMedix; National Cancer Institute (USA)
- Developer CorMedix
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Lipopolysaccharide inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Neuroblastoma
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer(In children, In infants) in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Neuroblastoma(In children, In infants) in USA
- 26 Apr 2019 9265445- relevant info already covered